MONTREAL, QUEBEC, CANADA--(Marketwire - June 18, 2007) - Enobia Pharma, announced today that it has appointed Hal Landy, MD as the Company's VP Medical Affairs & Chief Medical Officer. "With our pediatric focus and as we prepare to bring our first compound into the clinic, we welcome the leadership and experience in enzyme replacement therapies, pediatric disorders and orphan products that Dr. Landy brings to the Company", stated Robert Heft, PhD, President and CEO of Enobia Pharma.
